A Phase 3 interventional study of rivaroxaban 2.5 mg and rivaroxaban 15 mg in Atrial Fibrillation and Percutaneous Coronary Intervention, sponsored by Janssen Scientific Affairs, LLC. Completed at 356 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-19.
Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 10th largest by enrollment, is one of 4 that started in 2013, is one of 16 in phase 3, and was the 10th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 22+
China National Center for Cardiovascular Diseases · Sites in China
Ages 70+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–89
Xijing Hospital · Sites in China
Ages 18+
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19–99
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 17 · Phase 4 19
First in 2004; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,124 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 150 across the 45 interventional studies. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 45 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Scientific Affairs, LLC is the lead sponsor of 41 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
71 studies in Atrial Fibrillation by Johnson & Johnson: 7 open now, 12 under way, 1 of them phase 3. Of 57 finished, 39 (68%) have results posted.
Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, this one is the 4th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2013, is one of 12 in phase 3, and was the 24th registered.
Johnson & Johnson’s Atrial Fibrillation studies by the year they started, since 2003.
3 of the studies testing rivaroxaban in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06108414China National Center for Cardiovascular DiseasesLow-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation | 2026-12-31 |
| NCT05487950Assistance Publique - Hôpitaux de ParisRivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk | 2027-04-05 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 71 in Atrial Fibrillation:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or prasugrel or ticagrelor).
This is an open-label (both physician and participant know the treatment that the participant receives), randomized (study medication is assigned by chance), multicenter clinical study assessing the safety of 2 rivaroxaban treatment strategies and one vitamin K antagonist (VKA) treatment strategy in participants, who have paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF) and have had a percutaneous coronary intervention (PCI) with stent placement.
A target of 2,100 participants will be randomized into the study, with approximately 700 participants in each treatment strategy group. The randomization will be stratified by the intended duration of DAPT (1, 6, or 12 months).
The study consists of a screening phase, a 12-month open-label treatment phase, and an end-of-treatment/early withdrawal visit. The total duration of participation in the study for each participant is approximately 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
Drug: rivaroxaban 2.5 mg · Drug: rivaroxaban 15 mg · Drug: rivaroxaban 10 mg · Drug: aspirin (ASA) · Drug: clopidogrel · Drug: prasugrel · Drug: ticagrelor
dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
Drug: aspirin (ASA) · Drug: vitamin K antagonist (VKA) · Drug: clopidogrel · Drug: prasugrel · Drug: ticagrelor
rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months
Drug: rivaroxaban 15 mg · Drug: rivaroxaban 10 mg · Drug: clopidogrel · Drug: prasugrel · Drug: ticagrelor
One 2.5 mg tablet twice daily for up to twelve months
One 15 mg tablet once daily for up to twelve months
One 10 mg tablet once daily for up to twelve months
Low-dose aspirin tablet once daily for twelve months
Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
One 75 mg tablet once daily for up to twelve months
One 10 mg tablet once daily for up to twelve months
One 90 mg tablet twice daily for up to twelve months
Percentage of Participants With Clinically Significant Bleeding
Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (\>=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \>=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (\<) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.
Time frame: Up to Month 12
Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding
TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of \>= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \>=15 percent).
Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12
Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding
TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to \<5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent).
Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12
Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)
A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.
Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12
Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)
Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed.
Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12
Percentage of Participants With Cardiovascular Death
The percentage of participants with the first occurrence of cardiovascular death were evaluated.
Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12
Percentage of Participants With Myocardial Infarction
The percentage of participants with the first occurrence of Myocardial Infarction were evaluated.
Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12
Percentage of Participants With Stroke
The percentage of participants with the first occurrence of Stroke were evaluated.
Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12
Percentage of Participants With Stent Thrombosis
The percentage of participants with the first occurrence of stent thrombosis were evaluated.
Time frame: Up to Month 12 and end of DAPT-Month 1, 6 and 12
| Milestone | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Started | 709 | 709 | 706 |
| Treated | 696 | 706 | 697 |
| Completed | 550 | 557 | 492 |
| Not completed | 159 | 152 | 214 |
| Withdrew: Subject decision | 19 | 21 | 57 |
| Withdrew: Adverse event | 91 | 77 | 76 |
| Withdrew: Death | 20 | 22 | 22 |
| Withdrew: Protocol violation | 3 | 7 | 7 |
| Withdrew: Physician decision | 11 | 5 | 12 |
| Withdrew: Withdrawal by consent | 3 | 3 | 3 |
| Withdrew: Other | 12 | 17 | 37 |
Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (\>=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \>=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (\<) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Percentage of Participants With Clinically Significant Bleeding | 15.7 | 16.6 | 24.0 |
TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of \>= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \>=15 percent).
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Up to Month 12 (n= 696, 706, 697) | 2.0 | 1.7 | 2.9 |
| End of DAPT-1 Month (n= 0, 108,113) | NA | 0.9 | 4.4 |
| End of DAPT-6 Month (n= 0, 248,243) | NA | 2.8 | 3.7 |
| End of DAPT-12 Month (n= 0, 350,341) | NA | 1.1 | 1.8 |
TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to \<5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \<15 percent).
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Up to Month 12 (n= 696, 706, 697) | 1.0 | 1.0 | 1.9 |
| End of DAPT-1 Month (n= 0, 108, 113) | NA | 0.9 | 1.8 |
| End of DAPT-6 Month (n= 0, 248, 243) | NA | 0.4 | 2.5 |
| End of DAPT-12 Month (n= 0, 350, 341) | NA | 1.4 | 1.5 |
A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Up to Month 12 (n= 696, 706, 697) | 13.4 | 14.4 | 19.9 |
| End of DAPT-1 Month (n= 0, 108, 113) | NA | 16.7 | 18.6 |
| End of DAPT-6 Month (n= 0, 248, 243) | NA | 12.9 | 23 |
| End of DAPT-12 Month (n= 0, 350, 341) | NA | 14.9 | 18.2 |
Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed.
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | 5.9 | 5.1 | 5.2 |
| End of DAPT-1 Month (n= 0, 108, 112) | NA | 5.6 | 4.5 |
| End of DAPT-6 Month (n= 0, 248, 243) | NA | 6.5 | 3.7 |
| End of DAPT-12 Month (n= 0, 348, 340) | NA | 4 | 6.5 |
The percentage of participants with the first occurrence of cardiovascular death were evaluated.
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | 2.2 | 2 | 1.6 |
| End of DAPT-1 Month (n= 0, 108, 112) | NA | 1.9 | 1.8 |
| End of DAPT-6 Month (n= 0, 248, 243) | NA | 2.4 | 1.6 |
| End of DAPT-12 Month (n= 0, 348, 340) | NA | 1.7 | 1.5 |
The percentage of participants with the first occurrence of Myocardial Infarction were evaluated.
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | 2.7 | 2.4 | 3 |
| End of DAPT-1 Month (n= 0, 108, 112) | NA | 2.8 | 0.9 |
| End of DAPT-6 Month (n= 0, 248, 243) | NA | 2.8 | 2.5 |
| End of DAPT-12 Month (n= 0, 348, 340) | NA | 2 | 4.1 |
The percentage of participants with the first occurrence of Stroke were evaluated.
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | 1.2 | 1.4 | 1 |
| End of DAPT-1 Month (n= 0, 108, 112) | NA | 1.9 | 2.7 |
| End of DAPT-6 Month (n= 0, 248, 243) | NA | 2.4 | 0 |
| End of DAPT-12 Month (n= 0, 348, 340) | NA | 0.6 | 1.2 |
The percentage of participants with the first occurrence of stent thrombosis were evaluated.
| percentage of participants | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Up to Month 12 (n= 694, 704, 695) | 0.7 | 0.9 | 0.6 |
| End of DAPT-1 Month (n= 0, 108, 112) | NA | 1.9 | 0.9 |
| End of DAPT-6 Month (n= 0, 248, 243) | NA | 1.6 | 0.4 |
| End of DAPT-12 Month (n= 0, 348, 340) | NA | 0 | 0.6 |
Collected over Upto 12 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban 15 mg | — | 237/696 (34.1%) | 174/696 (25%) |
| Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | — | 225/706 (31.9%) | 210/706 (29.7%) |
| Vitamin K Antagonist (VKA) | — | 271/697 (38.9%) | 234/697 (33.6%) |
| Event | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| Cardiac FailureCardiac disorders | 21/696 | 16/706 | 31/697 |
| Angina UnstableCardiac disorders | 16/696 | 12/706 | 23/697 |
| Atrial FibrillationCardiac disorders | 13/696 | 21/706 | 23/697 |
| Angina PectorisCardiac disorders | 7/696 | 13/706 | 15/697 |
| PneumoniaInfections and infestations | 12/696 | 12/706 | 14/697 |
| Cardiac Failure CongestiveCardiac disorders | 7/696 | 4/706 | 11/697 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/696 | 6/706 | 10/697 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 7/696 | 7/706 | 9/697 |
| Chest PainGeneral disorders | 8/696 | 4/706 | 9/697 |
| SyncopeNervous system disorders | 1/696 | 4/706 | 8/697 |
| Event | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 67/696 | 59/706 | 82/697 |
| HaematomaVascular disorders | 21/696 | 31/706 | 61/697 |
| ContusionInjury, poisoning and procedural complications | 13/696 | 35/706 | 25/697 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 27/696 | 21/706 | 18/697 |
| HaematuriaRenal and urinary disorders | 18/696 | 14/706 | 14/697 |
| Gingival BleedingGastrointestinal disorders | 17/696 | 16/706 | 18/697 |
| Oedema PeripheralGeneral disorders | 14/696 | 12/706 | 18/697 |
| Angina PectorisCardiac disorders | 13/696 | 18/706 | 12/697 |
| DiarrhoeaGastrointestinal disorders | 12/696 | 18/706 | 11/697 |
| HypertensionVascular disorders | 17/696 | 2/706 | 7/697 |
The intent-to-treat analysis set included all randomized participants.
| Age, Continuous(years) | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) | Total |
|---|---|---|---|---|
| Mean | 70.4 ± 9.12 | 70 ± 9.11 | 69.9 ± 8.67 | 70.1 ± 8.97 |
| Sex: Female, Male(Participants) | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) | Total |
|---|---|---|---|---|
| Female | 181 | 174 | 188 | 543 |
| Male | 528 | 535 | 518 | 1581 |
| Region of Enrollment(participants) | Rivaroxaban 15 mg | Rivaroxaban 2.5 mg Twice Daily (BID)/15 mg Once Daily(QD) | Vitamin K Antagonist (VKA) | Total |
|---|---|---|---|---|
| Argentina | 32 | 27 | 23 | 82 |
| Australia | 3 | 7 | 5 | 15 |
| Belgium | 14 | 18 | 20 | 52 |
| Brazil | 14 | 14 | 13 | 41 |
| Bulgaria | 67 | 80 | 74 | 221 |
| Canada | 23 | 24 | 19 | 66 |
| Chile | 5 | 7 | 6 | 18 |
| Czech Republic | 17 | 9 | 14 | 40 |
| Denmark | 2 | 2 | 8 | 12 |
| France | 33 | 26 | 25 | 84 |
| Germany | 96 | 98 | 101 | 295 |
| Italy | 26 | 26 | 20 | 72 |
| Korea, Republic of | 11 | 11 | 17 | 39 |
| Malaysia | 1 | 5 | 5 | 11 |
| Mexico | 7 | 3 | 3 | 13 |
| Netherlands | 24 | 17 | 27 | 68 |
| Poland | 71 | 78 | 69 | 218 |
| Romania | 15 | 16 | 19 | 50 |
| Russian Federation | 90 | 86 | 89 | 265 |
| Sweden | 15 | 14 | 18 | 47 |
| Taiwan, Province of China | 8 | 8 | 9 | 25 |
| Turkey | 11 | 14 | 18 | 43 |
| Ukraine | 19 | 24 | 17 | 60 |
| United Kingdom | 48 | 44 | 39 | 131 |
| United States | 56 | 49 | 46 | 151 |
| South Africa | 1 | 2 | 2 | 5 |
Showing the first 100 of 356 sites across 25 countries. Choose a country and city above to see the rest.
Ran from May 2013 to primary completion in Jul 2016, 38 months.
Results were first posted in Jul 2017, 1 year after primary completion.
Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rivaroxaban · Aspirin · Vitamin K Antagonist
Janssen Scientific Affairs, LLC →